Diroximel fumarate (DRF) is a prodrug of monomethyl fumarate in a controlled-release formulation that rapidly and efficiently converts to MMF in the body[1].
[1]. Angela Wehr, et al. Relative Bioavailability of Monomethyl Fumarate after Administration of ALKS 8700 in Healthy Subjects (P1.403). Neurology. Apr 2018.
















